OTCMKTS:MRMD MariMed (MRMD) Stock Price, News & Analysis $0.10 -0.01 (-5.99%) As of 05/5/2025 03:47 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About MariMed Stock (OTCMKTS:MRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MariMed alerts:Sign Up Key Stats Today's Range$0.10▼$0.1150-Day Range$0.08▼$0.1252-Week Range$0.07▼$0.31Volume158,668 shsAverage Volume393,125 shsMarket Capitalization$39.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.Read More… MariMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreMRMD MarketRank™: MariMed scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MariMed.Read more about MariMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of MariMed is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MariMed is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMariMed has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MariMed's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of MariMed has been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently decreased by 10.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMariMed does not currently pay a dividend.Dividend GrowthMariMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of MariMed has been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently decreased by 10.53%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added MariMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MariMed insiders have not sold or bought any company stock.Percentage Held by Insiders18.99% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.18% of the stock of MariMed is held by institutions.Read more about MariMed's insider trading history. Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Stock News HeadlinesMariMed Announces First Quarter 2025 Earnings DateApril 8, 2025 | globenewswire.comMariMed Promotes Ryan Crandall to Chief Commercial OfficerApril 7, 2025 | globenewswire.comMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…May 6, 2025 | Crypto Swap Profits (Ad)MariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel ChewsApril 3, 2025 | globenewswire.comMarimed launches Nature’s Heritage Flower in IllinoisApril 1, 2025 | markets.businessinsider.comMariMed Launches Nature's Heritage™ Flower in IllinoisApril 1, 2025 | globenewswire.comMariMed Inc. (PNK:MRMD) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comMariMed Reports Record Revenue Amid Strategic GrowthMarch 6, 2025 | tipranks.comSee More Headlines MRMD Stock Analysis - Frequently Asked Questions How have MRMD shares performed this year? MariMed's stock was trading at $0.1158 at the start of the year. Since then, MRMD shares have decreased by 11.9% and is now trading at $0.1020. View the best growth stocks for 2025 here. How were MariMed's earnings last quarter? MariMed Inc. (OTCMKTS:MRMD) issued its quarterly earnings results on Wednesday, March, 5th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The company earned $39 million during the quarter, compared to the consensus estimate of $42 million. MariMed had a negative net margin of 10.97% and a negative trailing twelve-month return on equity of 2.75%. Read the conference call transcript. How do I buy shares of MariMed? Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MariMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that MariMed investors own include Canopy Growth (CGC), Innovative Industrial Properties (IIPR), NVIDIA (NVDA), Curaleaf (CURLF), Aurora Cannabis (ACB), Meta Platforms (META) and Tilray (TLRY). Company Calendar Last Earnings3/05/2025Today5/06/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:MRMD CIK1522767 Webmarimedadvisors.com Phone(617) 795-5140FaxN/AEmployees260Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,030,000.00 Net Margins-10.97% Pretax Margin-5.28% Return on Equity-2.75% Return on Assets-1.06% Debt Debt-to-Equity Ratio1.01 Current Ratio1.55 Quick Ratio0.73 Sales & Book Value Annual Sales$148.60 million Price / Sales0.27 Cash Flow$0.02 per share Price / Cash Flow5.59 Book Value$0.19 per share Price / Book0.54Miscellaneous Outstanding Shares388,710,000Free Float301,649,000Market Cap$39.65 million OptionableNot Optionable Beta3.15 20 Stocks to Sell NowGet This Free Report This page (OTCMKTS:MRMD) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MariMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MariMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.